These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 17982631

  • 1. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
    Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka K, Itoh K.
    Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
    [Abstract] [Full Text] [Related]

  • 2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W.
    Cancer Res; 2006 Dec 01; 66(23):11447-54. PubMed ID: 17145892
    [Abstract] [Full Text] [Related]

  • 3. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
    Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M.
    Prostate; 2004 Aug 01; 60(3):205-13. PubMed ID: 15176050
    [Abstract] [Full Text] [Related]

  • 4. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
    Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B.
    Cancer Res; 2003 Jul 15; 63(14):4107-11. PubMed ID: 12874014
    [Abstract] [Full Text] [Related]

  • 5. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y.
    Clin Cancer Res; 2006 May 01; 12(9):2689-97. PubMed ID: 16675560
    [Abstract] [Full Text] [Related]

  • 6. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
    Homma S, Harada M, Yano H, Ogasawara S, Shichijo S, Matsueda S, Komatsu N, Shomura H, Maeda Y, Sato Y, Todo S, Itoh K.
    Int J Oncol; 2006 Sep 01; 29(3):577-87. PubMed ID: 16865273
    [Abstract] [Full Text] [Related]

  • 7. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K, Teramoto K, Ozaki Y, Fujita T, Tezuka N, Sawai S, Watanabe H, Fujino S, Yokomise H, Ohkubo I.
    Int J Oncol; 2004 Dec 01; 25(6):1537-42. PubMed ID: 15547688
    [Abstract] [Full Text] [Related]

  • 8. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
    Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.
    Int Immunopharmacol; 2014 May 01; 20(1):59-65. PubMed ID: 24583149
    [Abstract] [Full Text] [Related]

  • 9. Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
    Wang Y, Takao Y, Harada M, Komatsu N, Ono T, Sata M, Itoh K, Yamada A.
    Cell Immunol; 2006 May 01; 241(1):38-46. PubMed ID: 16963008
    [Abstract] [Full Text] [Related]

  • 10. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y, Yamaguchi Y, Ohshita A, Minami K, Toge T.
    Anticancer Res; 2004 May 01; 24(2C):1193-200. PubMed ID: 15154646
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K.
    Prostate; 2003 Oct 01; 57(2):152-9. PubMed ID: 12949939
    [Abstract] [Full Text] [Related]

  • 12. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y, Aketa K, Nabeta C, Nakanishi K, Kamiguchi K, Mano Y, Kitamura H, Kobayashi J, Tsukahara T, Shijubo N, Sato N.
    Clin Cancer Res; 2005 Feb 01; 11(3):1000-9. PubMed ID: 15709165
    [Abstract] [Full Text] [Related]

  • 13. Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
    Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.
    J Immunother; 2015 Sep 01; 38(7):285-91. PubMed ID: 26261892
    [Abstract] [Full Text] [Related]

  • 14. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
    Hara M, Matsueda S, Tamura M, Takedatsu H, Tanaka M, Kawano K, Mochizuki K, Kamura T, Itoh K, Harada M.
    Int J Oncol; 2005 Nov 01; 27(5):1371-9. PubMed ID: 16211234
    [Abstract] [Full Text] [Related]

  • 15. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma.
    Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.
    Int Immunopharmacol; 2017 Mar 01; 44():197-202. PubMed ID: 28110220
    [Abstract] [Full Text] [Related]

  • 16. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J, Leng X, Peng J, Mou D, Pang X, Shang X, Chen W.
    Chin Med J (Engl); 2002 Jul 01; 115(7):1002-5. PubMed ID: 12150730
    [Abstract] [Full Text] [Related]

  • 17. Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types.
    Arima Y, Matsueda S, Yano H, Harada M, Itoh K.
    Int J Oncol; 2005 Oct 01; 27(4):981-8. PubMed ID: 16142314
    [Abstract] [Full Text] [Related]

  • 18. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 19. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K.
    Clin Cancer Res; 2004 Oct 01; 10(19):6695-702. PubMed ID: 15475460
    [Abstract] [Full Text] [Related]

  • 20. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
    Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A.
    J Orthop Res; 2001 May 01; 19(3):346-51. PubMed ID: 11398844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.